Nephros Reports 7% Revenue Growth to $5.2 Million in Q1 2026

Nephros, Inc. reported its financial results for the first quarter of 2026, revealing a net revenue of $5.2 million, a 7% increase from $4.9 million in the same period of 2025. The growth was primarily driven by an increase in product revenues, which rose to $5.0 million from $4.7 million year-over-year. However, the company experienced a decline in emergency response business, which had contributed significantly to revenues in the first quarter of 2025. The gross margin for the quarter was approximately 57%, down from 65% in the prior year, attributed to higher product costs and a shift in revenue mix towards lower-margin commercial sales.

Operating expenses for the quarter increased to $2.9 million from $2.6 million, with selling, general, and administrative expenses rising by 12% due to higher headcount and professional fees. Research and development expenses also saw a rise, reflecting increased salary costs associated with staffing. Despite these increases, Nephros reported a net income of $140,000, a significant decrease from $558,000 in the first quarter of 2025, largely due to the reduced operating income and the impact of higher costs.

In terms of operational metrics, Nephros reported a cash balance of $4.0 million as of March 31, 2026, down from $5.4 million at the end of 2025. The company’s total current assets increased slightly to $11.5 million, while total liabilities decreased to $3.1 million. The accumulated deficit stood at $143 million, indicating ongoing challenges in achieving sustained profitability. The company continues to focus on managing expenses and increasing sales to return to positive cash flow.

Strategically, Nephros is enhancing its product offerings, including a new solution validated for the reduction of Total PFAS, which broadens its market appeal. The company operates primarily in the medical and commercial water filtration markets, with a focus on infection control and dialysis applications. Nephros has also extended its License and Supply Agreement with Medica, ensuring a continued supply of critical filtration materials. The company’s sales strategy leverages both direct sales and partnerships with value-added resellers to expand its reach in various sectors.

Looking ahead, Nephros aims to maintain its growth trajectory by focusing on product innovation and market expansion. The company is optimistic about its ability to navigate current market conditions and achieve its operational goals, although it acknowledges the potential for fluctuations in demand and the need for effective cost management. Nephros plans to utilize its existing cash reserves to support its operations and strategic initiatives over the next 12 months.